You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The in vitro diagnostic test runs on the Illumina NovaSeq 6000 instrument and will be performed at Helix's San Diego CLIA-certified laboratory.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.